Just to be sure, do you mean cabotegravir (brand name Apretude), the long-acting HIV PrEP/treatment injectable? If you meant a different drug, tell me the exact name.
I don’t have real-time price data, but here are common reasons a price or list price for cabotegravir could rise recently, and what to check:
Possible reasons for a price increase
- Limited competition and manufacturing costs: Cabotegravir is a complex injectable with specialized manufacturing and cold-chain needs. When there’s only a single or small number of suppliers, price pressure can push up the list price.
- Supply and demand dynamics: If demand increases (e.g., more guideline-backed use, broader patient access), prices can adjust. Shortages of vials or active ingredients can also drive prices up.
- Payer negotiations and coverage: The price you see in a catalog (the list price) isn’t what every patient pays. Insurers, rebates, and manufacturer discounts can change what the patient actually owes; changes in payer contracts can shift list price perceptions even if net price for insurers moves differently.
- Regulatory or labeling changes: New indications, dosing schedules, or stability/storage requirements can affect manufacturing cost and pricing.
- Global price variation: Prices differ by country due to government pricing, rebates, taxes, and market size. A rise in one country may not reflect others.
What you can do if you’re trying to understand or manage cost
- Tell me your country and whether you’re asking about the US price or another market; I can tailor the explanation.
- Check current price details with the pharmacy or your insurer (cash price, negotiated price, and any patient assistance).
- Ask about manufacturer assistance programs: ViiV Healthcare (the company behind Apretude) often has patient support programs that can help with copays or access for eligible individuals.
- Look into insurance coverage and formularies: Some plans cover Apretude with lower co-pays, while others may push for alternative PrEP options.
- Consider alternatives if cost is prohibitive: Daily PrEP options (emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide) can be less expensive upfront, depending on coverage. Your clinician can help compare options in terms of cost and suitability.
- If you have a link or exact price data, share it and I’ll help interpret what it means and how it might affect access.
If you can specify the country and provide any price link or quote you’ve seen, I can give a more precise, tailored explanation.